Article ; Online: Mucormycosis: The hidden and forgotten disease.
Journal of applied microbiology
2022 Volume 132, Issue 6, Page(s) 4042–4057
Abstract: Mucormycosis is a rare but serious fungal infection caused by a group of moulds called mucormycetes. More attention has recently been paid to it due to its association with coronavirus disease 2019 (COVID-19). Thus, it is important to review the progress ...
Abstract | Mucormycosis is a rare but serious fungal infection caused by a group of moulds called mucormycetes. More attention has recently been paid to it due to its association with coronavirus disease 2019 (COVID-19). Thus, it is important to review the progress of studies on mucormycosis and highlight the important findings in relation to epidemiology, clinical manifestation, major risk factors, diagnostic strategies and management. An electronic literature search was performed in PubMed using the keywords: Rhizopus, Mucorales, mucormycosis, zygomycosis, zygomycetes, COVID-19, the drugs (azoles, posaconazole, isavuconazole, amphotericin B pharmaceutical preparations and caspofungin), combination therapy, diagnosis and clinical manifestations. Studies written in the English language from January 1960 to 2021 were considered for this review article. All search results were reviewed, and the relevance of each article was determined by the authors independently. The review emphasized the fact that the diagnosis of mucormycosis is difficult, it is necessary to have a high index of suspicion to identify it, surgical debridement should be done prior to the dissemination of infection to improve clinical outcomes and identifying underlying risk factors is important for proper treatment. Moreover, antifungal therapeutic options are few with polyenes and their combinations should be appropriate for empirical therapy while posaconazole and isavuconazole are best reserved for de-escalation, refractory cases or patients intolerant to amphotericin B. |
---|---|
MeSH term(s) | Amphotericin B/therapeutic use ; Antifungal Agents/therapeutic use ; COVID-19 ; Debridement ; Humans ; Mucorales ; Mucormycosis/diagnosis ; Mucormycosis/drug therapy ; Mucormycosis/epidemiology |
Chemical Substances | Antifungal Agents ; Amphotericin B (7XU7A7DROE) |
Language | English |
Publishing date | 2022-02-23 |
Publishing country | England |
Document type | Journal Article ; Review |
ZDB-ID | 1358023-1 |
ISSN | 1365-2672 ; 1364-5072 |
ISSN (online) | 1365-2672 |
ISSN | 1364-5072 |
DOI | 10.1111/jam.15487 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 259: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.